目的 探討替吉奧膠囊聯(lián)合尼妥珠單抗治療晚期頭頸部鱗狀細(xì)胞癌的臨床療效。方法 收集2012年5月-2015年5月在鄭州大學(xué)附屬腫瘤醫(yī)院治療的晚期頭頸部鱗狀細(xì)胞癌患者78例，隨機(jī)分為對(duì)照組（39例）和治療組（39例）。對(duì)照組靜脈滴注尼妥珠單抗注射液，100 mg加入5%葡萄糖注射液250 mL，1次/周，治療8周；治療組在對(duì)照組的基礎(chǔ)上口服替吉奧膠囊，第1周25 mg/次，2次/d，若可耐受則增至50 mg/次，2次/d，服用3周停1周，再服用3周。評(píng)價(jià)兩組患者臨床療效，同時(shí)比較治療前后兩組患者生活質(zhì)量調(diào)查表（QLQ-C30）評(píng)分和兩年生存率差異。結(jié)果 治療后，對(duì)照組總有效率為38.46%，疾病控制率為74.36%，分別顯著低于治療組患者的61.54%和92.31%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者各項(xiàng)QLQ-C30評(píng)分均顯著升高，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組患者各項(xiàng)QLQ-C30評(píng)分顯著高于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療兩年后，治療組總生存率為89.74%，顯著高于對(duì)照組的71.79%，兩組兩年生存率比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 替吉奧膠囊聯(lián)合尼妥珠單抗注射液治療晚期頭頸部鱗狀細(xì)胞癌疾病具有較高的控制率和生存率，可有效改善患者生活質(zhì)量，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To evaluate the clinical efficacy of Tegafur Gimeracil Oteracil Potassium Capsules combined with nimotuzumab in treatment of advanced head and neck squamous cell carcinoma. Methods Patients (78 cases) with advanced head and neck squamous cell carcinoma in Zhengzhou University Cancer Hospital from May 2012 to May 2015 were randomly divided into control (39 cases) and treatment (39 cases) groups. Patients in the control group were iv administered with Nimotuzumab Injection for 8 weeks, 100 mg added into 5% glucose injection 250 mL, once weekly. Patients in the treatment group were po administered with Tegafur Gimeracil Oteracil Potassium Capsules on the basis of the control group, 25 mg/time for the first week, then 50 mg/time for the tolerable patient, withdraw 1 week after taking 3 weeks, then they were treated for another 3 weeks, twice daily. After treatment, the clinical efficacy was evaluated, and the difference of QLQ-C30 scores and two-year survival rate in two groups before and after treatment was compared. Results After treatment, clinical efficacy and disease control rate in the control group were 38.46% and 74.36%, which were significantly lower than 61.54% and 92.31% in the treatment group, respectively, and there were differences between two groups (P<0.05). After treatment, the QLQ-C30 scores in two groups were significantly increased and there were differences in the same group (P<0.05). And the QLQ-C30 scores in the treatment group were significantly higher than that in the control group, with significant difference between two groups (P<0.05). After treatment for two years, the overall survival rate in the treatment group was 89.74%, which was significantly higher than 71.79% in the control group, and there were differences between two groups (P<0.05). Conclusion Tegafur Gimeracil Oteracil Potassium Capsules combined with nimotuzumab has high control rate and survival rate in treatment of advanced head and neck squamous cell carcinoma, and can effectively improve the quality of life, which has a certain clinical application value.